Bern, Switzerland, Thursday December 12, 2024 – CIS BIOPHARMA, a leading oncology-focused biotechnology company based in Basel, Switzerland, has achieved a significant milestone by securing funding from Innosuisse, the Swiss Innovation Agency, for its groundbreaking CBO-002 program. This achievement marks a key step forward in the company’s mission to develop novel targeted therapies for incurable brain tumors.
The CBO-002 program builds upon CIS BIOPHARMA’s successful collaborations with esteemed research partners such as the ETH Zurich, Paul Scherrer Institute, the center for Radiopharmaceuticals, the University of Applied Sciences Northwestern Switzerland (FHNW) and the University Children’s Hospital Zurich.
Dominik Brücher, Chief Technology Officer, says: «Our innovative approach to targeted radioligand therapy represents a significant leap forward in addressing the challenges of treating incurable brain tumors. By combining our novel linker technology with the emerging B7H3 target, we are poised to overcome the blood-brain barrier limitations that have hindered previous treatment efforts. This strategy enhances tumor targeting, potentially revolutionizing the treatment landscape for Glioblastoma Multiforme and other brain cancers.»
Christian Geraths, Chief Scientific Offer, says: «The development of our proprietary linker technology marks a technological advancement in the field of nanobody-based therapeutics. This innovation allows us to modulate the biophysical properties of our nanobodies. As we move into pre-clinical studies, we are confident that this platform will demonstrate its potential to significantly improve the efficacy and safety profile of targeted radioligand therapies for brain tumors.»
About CIS BIOPHARMA AG
CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.
